Not Signed In - Glenmark's Lead Candidate For Pain, GRC 6211, Enters Phase I In Europe
Thu, 14 Dec 2006 08:00 AM EST
... Glenmark Pharmaceuticals S.A. [GPSA], the wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd. [Glenmark], has applied for Phase I clinical trials in Europe, for GRC 6211, its leading vanniloid receptor [VR1] antagonist compound for a range of pain indications like osteoarthritis, dental pain, neuropathic pain and urinary incontinence. [click link for full article] ...
Related Topics
- Lead Poisoning
- Lead
- Pain
- Pain - Chronic
- Chronic Pain
- Pain Control
- Chest Pain
- Pain, Chest
- Low Back Pain
- Blood Lead Levels
- Back Pain
- Abdominal Pain
- Europe, Western
- Eastern Europe and Northern Asia
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Poisoning
- Sciatica
- Usher Syndrome: New Insights Lead to Earlier Treatment
- Complex Regional Pain Syndrome
email this page
print this page
bookmark this page
feedback on this page
